Guangdong Marubi Biotechnology Co., Ltd.

SHSE:603983 Stock Report

Market Cap: CN¥13.6b

Guangdong Marubi Biotechnology Balance Sheet Health

Financial Health criteria checks 5/6

Guangdong Marubi Biotechnology has a total shareholder equity of CN¥3.4B and total debt of CN¥250.9M, which brings its debt-to-equity ratio to 7.3%. Its total assets and total liabilities are CN¥4.4B and CN¥991.3M respectively. Guangdong Marubi Biotechnology's EBIT is CN¥264.8M making its interest coverage ratio -4.6. It has cash and short-term investments of CN¥2.1B.

Key information

7.3%

Debt to equity ratio

CN¥250.91m

Debt

Interest coverage ratio-4.6x
CashCN¥2.10b
EquityCN¥3.44b
Total liabilitiesCN¥991.30m
Total assetsCN¥4.44b

Recent financial health updates

Guangdong Marubi Biotechnology (SHSE:603983) Has A Pretty Healthy Balance Sheet

May 29
Guangdong Marubi Biotechnology (SHSE:603983) Has A Pretty Healthy Balance Sheet

Recent updates

Investors Could Be Concerned With Guangdong Marubi Biotechnology's (SHSE:603983) Returns On Capital

Dec 25
Investors Could Be Concerned With Guangdong Marubi Biotechnology's (SHSE:603983) Returns On Capital

Calculating The Fair Value Of Guangdong Marubi Biotechnology Co., Ltd. (SHSE:603983)

Dec 09
Calculating The Fair Value Of Guangdong Marubi Biotechnology Co., Ltd. (SHSE:603983)

Is Now The Time To Put Guangdong Marubi Biotechnology (SHSE:603983) On Your Watchlist?

Nov 22
Is Now The Time To Put Guangdong Marubi Biotechnology (SHSE:603983) On Your Watchlist?

Market Participants Recognise Guangdong Marubi Biotechnology Co., Ltd.'s (SHSE:603983) Earnings Pushing Shares 27% Higher

Sep 26
Market Participants Recognise Guangdong Marubi Biotechnology Co., Ltd.'s (SHSE:603983) Earnings Pushing Shares 27% Higher

Guangdong Marubi Biotechnology's (SHSE:603983) Promising Earnings May Rest On Soft Foundations

Aug 30
Guangdong Marubi Biotechnology's (SHSE:603983) Promising Earnings May Rest On Soft Foundations

Investors Could Be Concerned With Guangdong Marubi Biotechnology's (SHSE:603983) Returns On Capital

Jun 19
Investors Could Be Concerned With Guangdong Marubi Biotechnology's (SHSE:603983) Returns On Capital

Guangdong Marubi Biotechnology (SHSE:603983) Has A Pretty Healthy Balance Sheet

May 29
Guangdong Marubi Biotechnology (SHSE:603983) Has A Pretty Healthy Balance Sheet

Are Guangdong Marubi Biotechnology Co., Ltd. (SHSE:603983) Investors Paying Above The Intrinsic Value?

May 07
Are Guangdong Marubi Biotechnology Co., Ltd. (SHSE:603983) Investors Paying Above The Intrinsic Value?

Guangdong Marubi Biotechnology Co., Ltd.'s (SHSE:603983) Share Price Matching Investor Opinion

Mar 27
Guangdong Marubi Biotechnology Co., Ltd.'s (SHSE:603983) Share Price Matching Investor Opinion

Guangdong Marubi Biotechnology (SHSE:603983) Will Be Hoping To Turn Its Returns On Capital Around

Feb 29
Guangdong Marubi Biotechnology (SHSE:603983) Will Be Hoping To Turn Its Returns On Capital Around

Financial Position Analysis

Short Term Liabilities: 603983's short term assets (CN¥2.6B) exceed its short term liabilities (CN¥969.6M).

Long Term Liabilities: 603983's short term assets (CN¥2.6B) exceed its long term liabilities (CN¥21.7M).

Debt to Equity History and Analysis

Debt Level: 603983 has more cash than its total debt.

Reducing Debt: 603983's debt to equity ratio has increased from 0% to 7.3% over the past 5 years.

Debt Coverage: 603983's debt is well covered by operating cash flow (134.9%).

Interest Coverage: 603983 earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 11:23
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Guangdong Marubi Biotechnology Co., Ltd. is covered by 24 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lei YangCGS International
Jin LiChangjiang Securities Co. LTD.
Lei YangChina Galaxy International Securities (Hong Kong)